Growth is expected to be supported by ENHERTU's continued expansion. Profit attributable to owners of the company for FY2024 was revised upward by ¥15 billion to ¥240 billion, driven by improved ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Top-line data from the study showed that people treated with amycretin experienced a weight loss of 9.7% for the 1.25 mg dose over 20 weeks ... AZN & Daiichi’s Enhertu for Expanded Breast ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

Enhertu was discovered by Daiichi Sankyo and is being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. HER2 is a receptor protein that accelerates the growth of cancer cells.

1. Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for Enhertu. Roche. News release. January 31 ...

NEW YORK – Roche announced on Friday that its Pathway Anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody has received a label expansion from the US Food and Drug Administration as a companion ...

For more information, see our expert panel. Stock trading apps empower investors to buy and sell securities directly from the convenience of their mobile devices. The best stock trading apps ...

Key factors for dividend stock selection include company stability and the ability to grow payouts over time. Key findings are powered by ChatGPT and based solely off the content from this article.

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...